Company intelligence / Profile preview
Aromics
Barcelona, Catalonia, Spainaromics.es ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Aromics’ lead compound is a small molecule drug targeting malignant mesothelioma and other cancers. It works by binding to mRNA and blocking production of a key enzyme needed for tumor growth. The company uses omics technologies to identify biomarkers and improve patient selection. Their approach aims to overcome resistance seen with current chemotherapy options like pemetrexed and cisplatin. Clinical results are not detailed publicly but the company’s focus remains on drug-resistant cancers with high unmet need.[1][3][4]
- Therapeutic areas
- OtherOncology
- Modalities
- Small moleculesOmics-based diagnostics (genomics, proteomics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; participates in EU-funded projects such as Bermes Project[3]
Beyond the preview
Go deeper on Aromics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aromics.